NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDRA Life Sciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$4.75+0.01 (+0.21%)
Close on Oct 19, 2026
- Market cap
- $11.76M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -196.6% | -291.6% | |
| Return on assets | – | -147.1% | -169.2% | |
| Current ratio | 0.14 | 8.32 | 1.29 | |
| Interest coverage | -24.9× | – | – | |
| Inventory turnover | – | 0.0× | – | |
| Capex to revenue | – | – | – | |
| Diluted shares | 1M | 19M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
ENDRA Life Sciences generated $46.02M from operations and spent $314.74K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$46.02M
Used
$314.74K
Capital expenditure$314.74K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-158669.6%
×Asset turnover0.00×
×Equity multiplier1.16×
=Return on equity, FY2018-170.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2018 | -158669.6% | 0.00× | 1.16× | -170.0% |
| FY2017 | -1529.2% | 0.11× | 1.51× | -245.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$7.03M
- Cash generatingOperating cash flow above zero-$5.18M
- Return on assets improvedROA up on the prior year-170.4% → -157.8%
- Earnings backed by cashOperating cash flow above net income-$5.18M vs -$7.03M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.67 → 1.29
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –